Last reviewed · How we verify
NCT06153888: ULRICA
ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study
NA trial testing Ultrafiltration rate in Fluid Overload in 40 participants. Currently enrolling.
30 March 2026
Quick facts
| Lead sponsor | Umeå University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 20 March 2023 |
| Primary completion | 30 March 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Ultrafiltration rate
Conditions studied
- Fluid Overload — all drugs for Fluid Overload →
- Dialysis; Complications — all drugs for Dialysis; Complications →
Sponsor
Umeå University
Who can join
18 and older, any sex, with Fluid Overload or Dialysis; Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients performing chronic hemodialysis (HD) retain more or less water between dialyses. The water is removed by ultrafiltration and usually during the cleansing of waste products - the HD. The length of HD is usually the same as the time of fluid removal while sometimes this may differ. There is no clear guideline. In previous research the investigator noted that the heart releases more NT-pro-BNP during HD in numerous of the patients. The present study aims to clarify if the speed of fluid removal during HD is a factor that may alter the release of cardiac markers during HD. If so the recommendations for the prescription of HD can be updated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06153888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fluid Overload
Currently open trials in the same condition.
- NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
- NCT07275658 — Timing and Dose of Fluid Deresuscitation in Critically Ill Patients · recruiting
- NCT06697470 — Muscle and Subcutaneous Tissue Variation by Ultrasound and Impedance Linked to Fluid Balance in ICU Patients · recruiting
- NCT06539026 — Inferior Vena Cava Collapsibility Index Guide for Preoperative Fluid Therapy in Preeclampsia · NA · recruiting
- NCT06418022 — Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning · NA · recruiting
Other Umeå University trials
Trials by the same sponsor.
- NCT07407946 — Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion · NA · recruiting
- NCT07346820 — VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation · not yet recruiting
- NCT07417358 — Single-Stapled Technique for Colorectal Anastomosis · recruiting
- NCT07316426 — Preoptimisation in Ventral Hernia Surgery · NA · recruiting
- NCT07170722 — Sub-threshold DRG Stimulation vs Sham in Established Responders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06153888 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Umeå University
- Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06153888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing